171
Participants
Start Date
March 31, 2008
Primary Completion Date
March 31, 2011
Study Completion Date
April 30, 2012
Bevacizumab (avastin)
Bevacizumab intravenous \[IV\] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])
Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous \[IV\] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
AG-013736 (axitinib)
Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.
FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
Oxaliplatin (85 mg/m²) intravenous infusion \[IV\] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
AG-013736 (axitinib)
Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.
FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])
Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Bevacizumab (avastin)
Bevacizumab intravenous infusion \[IV\] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Pfizer Investigational Site, Genova
Pfizer Investigational Site, Baltimore
Pfizer Investigational Site, Midlothian
Pfizer Investigational Site, Mechanicsville
Pfizer Investigational Site, Richmond
Pfizer Investigational Site, Richmond
Pfizer Investigational Site, Madrid
Pfizer Investigational Site, Atlanta
Pfizer Investigational Site, Ringgold
Pfizer Investigational Site, Fort Myers
Pfizer Investigational Site, Fort Myers
Pfizer Investigational Site, Cape Coral
Pfizer Investigational Site, Fort Myers
Pfizer Investigational Site, Port Charlotte
Pfizer Investigational Site, Cape Coral
Pfizer Investigational Site, Montpellier
Pfizer Investigational Site, Naples
Pfizer Investigational Site, Naples
Pfizer Investigational Site, Bonita Springs
Pfizer Investigational Site, Bradenton
Pfizer Investigational Site, Englewood
Pfizer Investigational Site, Sarasota
Pfizer Investigational Site, Sarasota
Pfizer Investigational Site, Venice
Pfizer Investigational Site, Venice
Pfizer Investigational Site, Padua
Pfizer Investigational Site, Mobile
Pfizer Investigational Site, Gallatin
Pfizer Investigational Site, Franklin
Pfizer Investigational Site, Hermitage
Pfizer Investigational Site, Lebanon
Pfizer Investigational Site, Murfreesboro
Pfizer Investigational Site, Smyrna
Pfizer Investigational Site, Nashville
Pfizer Investigational Site, Nashville
Pfizer Investigational Site, Nashville
Pfizer Investigational Site, Nashville
Pfizer Investigational Site, Nashville
Pfizer Investigational Site, Hixson
Pfizer Investigational Site, Chattanooga
Pfizer Investigational Site, Germantown
Pfizer Investigational Site, Paris
Pfizer Investigational Site, Union City
Pfizer Investigational Site, New Albany
Pfizer Investigational Site, Crestview Hills
Pfizer Investigational Site, Paducah
Pfizer Investigational Site, Paducah
Pfizer Investigational Site, Hamilton
Pfizer Investigational Site, Fairfield
Pfizer Investigational Site, Cincinnati
Pfizer Investigational Site, Cincinnati
Pfizer Investigational Site, Cincinnati
Pfizer Investigational Site, Cincinnati
Pfizer Investigational Site, Cincinnati
Pfizer Investigational Site, Cincinnati
Pfizer Investigational Site, Dubuque
Pfizer Investigational Site, Lille
Pfizer Investigational Site, Paris
Pfizer Investigational Site, Corpus Christi
Pfizer Investigational Site, Aurora
Pfizer Investigational Site, Los Angeles
Pfizer Investigational Site, Santa Monica
Pfizer Investigational Site, Pleasant Hill
Pfizer Investigational Site, Antioch
Pfizer Investigational Site, San Leandro
Pfizer Investigational Site, Villejuif
Pfizer Investigational Site, Los Angeles
Pfizer Investigational Site, Fort Myers
Pfizer Investigational Site, Greenfield Park
Pfizer Investigational Site, Lévis
Pfizer Investigational Site, Montreal
Pfizer Investigational Site, Roma
Pfizer Investigational Site, Roma
Pfizer Investigational Site, Kashiwa
Pfizer Investigational Site, Suntougun
Pfizer Investigational Site, Chuo-ku
Pfizer Investigational Site, Warsaw
Pfizer Investigational Site, Warsaw
Pfizer Investigational Site, Daegu
Pfizer Investigational Site, Jeollanam-do
Pfizer Investigational Site, Seoul
Pfizer Investigational Site, L'Hospitalet de Llobregat
Pfizer Investigational Site, Sabadell
Lead Sponsor
Pfizer
INDUSTRY